Influence of cardiogenic shock with or without the use of intra-aortic balloon pump on mortality in patients with ST-segment elevation myocardial infarction

• Published in: International journal of cardiology. Heart & vasculature Vol. 6; no. C; pp. 19 - 24
• Main Authors: Jensen, Jesper Khedri, Thayssen, Per, Antonsen, Lisbeth, Hougaard, Mikkel, Junker, Anders, Pedersen, Knud Erik, Jensen, Lisette Okkels
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01-03-2015; Elsevier
• Subjects: Cardiogenic shock; Intra-aortic balloon pump; ST-segment elevation myocardial infarction; Cardiogenic shock; Intra-aortic balloon pump; ST-segment elevation myocardial infarction
• ISSN: 2352-9067; 2352-9067
• DOI: 10.1016/j.ijcha.2014.12.006

Cardiogenic shock is a serious complication of a ST-segment elevation myocardial infarction (STEMI). We compared short- and long-term mortality among (1) STEMI patients with and without cardiogenic shock and (2) STEMI patients with cardiogenic shock with and without the use of an intra-aortic balloon pump (IABP).
From January 1, 2002 to December 31, 2010, all patients presenting with STEMI and treated with primary percutaneous coronary intervention (PCI) were identified. The hazard ratio (HR) for death was estimated using a Cox regression model, controlling for potential confounding.
The study cohort consisted of 4293 STEMI patients: 286 (6.7%) with and 4007 (93.3%) without cardiogenic shock. Compared with patients without cardiogenic shock, patients with cardiogenic shock were older, and more likely to have diabetes mellitus, multi-vessel disease, anterior myocardial infarction (MI) or bundle-branch block MI and a reduced creatinine clearance.
Among patients with cardiogenic shock vs. without shock, 30-day cumulative mortality was 57.3% vs. 4.5% (p<0.001), one-year cumulative mortality was 60.7% vs. 8.2% (p<0.001) and five-year mortality was 65.0% vs. 18.9% (p<0.001). STEMI with cardiogenic shock was associated with higher 30-day mortality (adjusted HR=12.89 [95% CI: 9.72–16.66]), 1-year mortality (adjusted HR=8.83 [95% CI: 7.06–11.05]) and five-year mortality (adjusted HR=6.39 [95% CI: 5.22–7.80]). IABP was used in 71 (25%) patients with cardiogenic shock and was associated with improved 30-day outcome (adjusted HR=0.48 [95% CI: 0.28–0.83]).
Patients with STEMI and cardiogenic shock had substantial short- and long-term mortality that may be improved with IABP implantation. More studies on use of IABP in such patients are warranted.